LOGIN  |  REGISTER
Chimerix

BUY $CMRX

Buy $CMRX on Charles Schwab

Buy $CMRX on ETrade

Buy $CMRX on Public.com

Buy $CMRX on Fidelity

Buy $CMRX on  Robinhood

Buy $CMRX on Webull

Chimerix to Present at H.C. Wainwright 26th Annual Global Investment Conference

September 03, 2024 | Last Trade: US$2.99 0.14 4.91

DURHAM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, will present a corporate presentation at the H.C. Wainwright 26th Annual Global Investment Conference made available on Monday, September 9, 2024 at 7:00 a.m. ET.

An audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at www.ir.chimerix.com, where it will be archived for approximately 90 days.

About Chimerix

Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.   The Company is conducting Phase 1 dose escalation studies of ONC206 to evaluate safety and PK data.

CONTACT:

Will O’Connor
Stern Investor Relations
212-362-1200
This email address is being protected from spambots. You need JavaScript enabled to view it.

BUY $CMRX

Buy $CMRX on Charles Schwab

Buy $CMRX on ETrade

Buy $CMRX on Public.com

Buy $CMRX on Fidelity

Buy $CMRX on  Robinhood

Buy $CMRX on Webull

Stock Quote

BUY $CMRX

Buy $CMRX on Charles Schwab

Buy $CMRX on ETrade

Buy $CMRX on Public.com

Buy $CMRX on Fidelity

Buy $CMRX on  Robinhood

Buy $CMRX on Webull

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE
Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB